STAAR Surgical Reports Record Q1 Sales and Return to Profitability, Exceeding Expectations
STAA has more than doubled off its 52-week low of $15.585.
Summary
STAAR Surgical announced a strong Q1 2026, achieving record net sales of $93.5 million and returning to profitability with a net income of $5.2 million, a significant turnaround from the prior year's losses.
Key Events · Earnings and Guidance · STAA
-
Record Q1 Net Sales
Net sales for Q1 2026 reached $93.5 million, a 119.6% increase compared to $42.6 million in Q1 2025, primarily driven by strong performance in China.
-
Return to Profitability
The company reported a net income of $5.2 million ($0.10 diluted EPS) for Q1 2026, a significant improvement from a net loss of $54.2 million ($-1.10 diluted EPS) in Q1 2025.
-
Significant Gross Margin Improvement
Gross profit margin increased to 73.6% in Q1 2026 from 65.8% in Q1 2025, reflecting cost reduction initiatives and improved production volumes.
-
Reduced Restructuring Charges
Restructuring, impairment, and related charges decreased substantially to $2.7 million in Q1 2026 from $22.7 million in Q1 2025.
Analysis · STAA · Industrial Applications And Services
STAAR Surgical has reported a significant financial turnaround in Q1 2026, moving from a substantial net loss in the prior year to profitability. Net sales more than doubled year-over-year, driven by strong performance in China, and gross margins improved considerably. This marks a strong recovery from fiscal year 2025, which saw a significant drop in sales and a widened net loss. While cash and investments decreased in Q1 due to front-loaded payments, the company anticipates generating cash for the remainder of the year. This full quarterly report confirms and elaborates on the positive preliminary results announced earlier, reinforcing a positive shift in the company's operational and financial health.
At the time of this filing, STAA was trading at $34.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $15.59 to $30.81. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.